Can B (CANB) Common Stock : $84.94 Mil (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Can B Common Stock?

Can B's quarterly common stock increased from Mar. 2024 ($84.36 Mil) to Jun. 2024 ($85.27 Mil) but then declined from Jun. 2024 ($85.27 Mil) to Sep. 2024 ($84.94 Mil).

Can B's annual common stock increased from Dec. 2021 ($49.68 Mil) to Dec. 2022 ($79.74 Mil) and increased from Dec. 2022 ($79.74 Mil) to Dec. 2023 ($83.38 Mil).

Can B Common Stock Historical Data

The historical data trend for Can B's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can B Common Stock Chart

Can B Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

24.32

30.87

49.68

79.74

83.38

Can B Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															82.80	83.38	84.36	85.27	84.94

Can B Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Can B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Can B Corp (OTCPK:CANB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 South Broadway, Suite 120, Hicksville, NY, USA, 11801

Website

https://www.canbiola.com

Can B Corp is engaged in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devices. The company focuses on developing a line of proprietary products in the Hemp Industry.

Executives

Mckenzie Webster Ltd	10 percent owner	DMS HOUSE, DR. ROYCE DRIVE, GEORGE TOWN, GRAND CAYMAN E9 KY1-1102
Stanley L Teeple	director, officer: CFO, Director, and Secretary	94 ARTHUR HILL COURT, HENDERSON NV 89014
Andrew Holtmeyer	officer: EVP Business Development	65 LAUREN AVE, SUITE 301, HUNTINGTON STATION NY 11746
Heggenhougen Rolv	director	90 NORTH CHURCH STREET, GEORGETOWN E9 KY1-1102
David J Posel	officer: COO	6103 CARMEL LN SE, LACEY WA 98503
Rolv Heggenhougen	10 percent owner	445 NE 12TH AVENUE, FORT LAUDERDALE FL 33301
Marco Alfonsi	director, 10 percent owner, officer: CEO, Board Member	44 EAST END AVENUE, HICKSVILLE NY 11801
Carl Dilley	director	15500 ROOSEVELT BLVD., SUITE 301, CLEARWATER FL 33760